Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Aaron S. Mansfield(Chinese University of Hong Kong), Keith T. Flaherty(Massachusetts General Hospital), Noeen Malik(Tempus Labs (United States)), Lyndsay N. Harris(University Hospitals Cleveland Medical Center), Elad Sharon(National Cancer Institute), Peter J. O’Dwyer(University of Pennsylvania), Larry Rubinstein(National Cancer Institute), David R. Patton(National Cancer Institute), Lisa M. McShane(National Cancer Institute), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Ranee Mehra(Fox Chase Cancer Center), A. P. Chen(National Cancer Institute), Barbara A. Conley, Patrick M. Forde(Johns Hopkins University), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Scott A. Tomlins(University of Michigan), Robert J. Gray(Eastern Cooperative Oncology Group), Stanley R. Hamilton(Johns Hopkins Medicine), Alice T. Shaw(Massachusetts General Hospital), Naoko Takebe(National Cancer Institute), Edith P. Mitchell(Thomas Jefferson University Hospital), Daniel H. Hovelson(Michigan Medicine), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), S. Li(Dana-Farber Cancer Institute), P. Mickey Williams(Frederick National Laboratory for Cancer Research), James R. Wright(Dalhousie University), Kelsey Poorman(Caris Life Sciences (United States)), Jia-Hui Zeng(Caris Life Sciences (United States)), Christopher H. Lieu(University of Colorado Denver)
Cited by 42
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k